USEUROPEAFRICAASIA 中文双语Français
China
Home / China / World

US to adopt limits on chimp research

China Daily | Updated: 2011-12-17 07:26

WASHINGTON - The US government said on Thursday that it would adopt strict new limits on using chimpanzees in medical research, after a prestigious scientific group recommended that experiments with humans' closest relative be done only as a last resort.

The National Institutes of Health (NIH) agreed that science has advanced enough that chimps seldom would be needed to help develop new medicines.

NIH Director Francis Collins temporarily barred new federal funding for research involving chimps, and said a working group will review about 37 current projects involving the animals to determine whether they should be phased out.

The chimps' similarity with people "demands special consideration and respect", Collins said.

These apes' genetic similarity to people has long caused a quandary. It is what has made them so valuable to scientists for nearly a century. They were vital in creating a vaccine for hepatitis B, for example, and were even shot into space to make sure the trip would not kill astronauts.

That close relationship also has had animal rights groups arguing that using chimps for biomedical research is unethical, even cruel.

Chimp research was already dwindling fast as scientists turned to less costly and ethically charged alternatives.

But Thursday's decision was triggered by an uproar last year over the fate of 186 semi-retired research chimps that the NIH, to save money, planned to move from a New Mexico facility to an active research lab in Texas.

Where and how to house those animals, and others scattered around the country who probably no longer will be needed, are among the issues that Collins said a high-level government working group will decide as it determines how to implement the new research restrictions.

The Institute of Medicine's recommendation on Thursday stopped short of the outright ban that animal rights activists had pushed. Instead, it urged strict limits on biomedical research, testing new drugs or giving the animal a disease and would allow using chimps only if studies could not be done on other animals or people themselves, and if foregoing the chimp work would hinder progress against life-threatening or debilitating conditions.

The panel advised the government to limit the use of chimps in behavioral and genetic research as well, saying such studies must provide insights that otherwise are unattainable and use techniques that minimize any pain or distress.

"We understand and feel compelled by the moral cost of using chimpanzees in research," said bioethicist Jeffrey Kahn of Johns Hopkins University, who chaired the Institute of Medicine panel. "We have established criteria that will set the bar quite high for justification of the use of chimpanzees."

The US is one of only two countries known to still conduct medical research with chimpanzees; the other is Gabon, in Africa. The European Union essentially banned such research last year.

Here, too, the practice was becoming uncommon. The Institute of Medicine's investigation found that over the past 10 years, the NIH has paid for just 110 projects of any type that involved chimps. There are less than 1,000 chimps available for medical research in the country. While it is impossible to say how many have been used in privately funded pharmaceutical research, the industry is shifting to higher-tech and less costly research methods. One drug company, GlaxoSmithKline, adopted an official policy ending its use of great apes, including chimpanzees, in research.

Associated Press

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US